title: Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.
abstract: Both pioglitazone and rosiglitazone are effective hypoglycaemic agents in monotherapy as in combined therapy. Interestingly, their reducing effect on fasting glycaemia and HbA1c is maintained over time, suggesting a potential protective effect of glitazones on the pancreatic beta-cells. The effects on lipids of pioglitazone are more favourable than those of rosiglitazone. Indeed, pioglitazone appears to be well suited for diabetic dyslipidaemia, increasing high-density lipoprotein (HDL)-cholesterol, decreasing triglycerides and small, dense low-density (LDL) particles with usually no effect on plasma LDL-cholesterol. Rosiglitazone also increases HDL-cholesterol, but has no effect on triglycerides and increases plasma LDL-cholesterol.
authors.affiliation: Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, Hôpital du Bocage, C.H.U. Dijon, France. bruno.verges@chu-dijon.fr
authors.forename: Bruno
authors.initials: B
authors.lastname: Vergès
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008055:Lipids; D000077205:Pioglitazone; D000077154:Rosiglitazone; D045162:Thiazolidinediones